RES-Seq—a barcoded library of drug-resistant Leishmania donovani allowing rapid assessment of cross-resistance and relative fitness

Genomic and Phenotypic Characterization of Experimentally Selected Resistant Leishmania donovani Reveals a Role for Dynamin-1-Like Protein in the Mechanism of Resistance to a Novel Antileishmanial Compound

(2022) Aya Hefnawy et al.   mBio

Oligo targeting for profiling drug resistance mutations in the parasitic trypanosomatids

(2022) Simone Altmann et al.   NUCLEIC ACIDS RESEARCH

Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas’ Disease

(2021) Marta L. Lima et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

(2021) Charles E. Mowbray et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani

(2020) Richard J. Wall et al.   ACS Infectious Diseases

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

(2020) Advait Nagle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors

(2020) Manuel Saldivia et al.   Nature Microbiology

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

(2019) Susan Wyllie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

(2018) Susan Wyllie et al.   NATURE

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani

(2018) Victoriano Corpas-Lopez et al.   ACS Infectious Diseases

A CRISPR Cas9 high-throughput genome editing toolkit for kinetoplastids

(2017) Tom Beneke et al.   Royal Society Open Science

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

(2016) Shilpi Khare et al.   NATURE

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania

(2016) Susan Wyllie et al.   PLoS Pathogens

Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease

(2015) Jennifer Riley et al.   PLoS Neglected Tropical Diseases

Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease

(2015) Shilpi Khare et al.   PLoS Pathogens

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections

(2013) ROB DON et al.   PARASITOLOGY

Assessing the Essentiality of Leishmania donovani Nitroreductase and Its Role in Nitro Drug Activation

(2012) S. Wyllie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY